Across the cagrilintide clinical program, the dominant tolerability issues have been gastrointestinal: nausea, reduced appetite, constipation, and, less commonly, vomiting a profile shared with pramlintide and with GLP-1 agonists, and mechanistically expected from a compound that slows the stomach and engages the area postrema
I have been using it for almost 2 months now and the truth is that I have noticed a great improvement
By following medical guidance and staying committed to your wellness journey, you can achieve lasting success with GLP-1 treatments
They're small, fat-friendly, and active in microgram-to-low-milligram doses
While the FDA allows compounding under specific shortage conditions, the agency doesnt review or approve these customized drugs for safety, purity, or efficacy